Cas:110-95-2 TMPDA manufacturer & supplier

Chemical Name:TMPDA

CAS.NO:110-95-2

Synonyms:bis[(dimethylamino)methyl]methane;N,N,N′,N′-Tetramethyl-1,3-propanediamine;N,N,N’,N’-Tetramethylpropane-1,3-diamine;1,3-Propanediamine, N,N,N,N-tetramethyl-;N1,N1,N3,N3-Tetramethylpropane-1,3-diamine;Tetramethyl-1,3-diaminopropane;MFCD00008337;1,3-Bis(dimethylamino)propane;N,N,N’,N’-Tetramethyltrimethylenediamine;N,N,N‘,N‘-Tetramethyl-1,3-propanediamine;TMPDA;N,N,N’,N’-Tetramethyl-1,3-propanediamine;N,N,N’,N’-TetraMethyl-1,3-diaMinopropane;EINECS 203-818-8

Molecular Formula:C₇H₁₈N₂

Molecular Weight:130.231

HS Code:2921290000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:143.3±8.0 °C at 760 mmHg

Density:0.8±0.1 g/cm3

Index of Refraction:1.442

PSA:6.48000

Exact Mass:130.147003

LogP:0.43

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2734 8/PG 2

Packing Group:III

Contact us for information like bis[(dimethylamino)methyl]methane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 203-818-8 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tetramethyl-1,3-diaminopropane Use and application,1,3-Bis(dimethylamino)propane technical grade,usp/ep/jp grade.

Related News: This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. TMPDA manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. TMPDA supplier Beijing will strengthen its monitoring of overseas drug market and collect global prices for imported medicines, Friday��s guideline said. TMPDA vendor With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. TMPDA factory High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.